Navigation Links
Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

http://www.reportlinker.com/p0286296/Urological-Disorders-Therapeutics-to-2016---Increasing-Awareness-and-Aging-Population-will-Drive-the-Benign-Prostatic-Hyperplasia-and-Urinary-Incontinence-Markets.html

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Summary

GBI Research's Therapeutic Analysis report, "Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets", provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

- Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).

- Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.

- Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.

- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Global Urological Disorders Market: Introduction 10

2.1 GBI Research Report Guidance 11

3 Global Urological Disorders Market: Market Overview 12

3.1 Introduction 12

3.2 Revenue Forecasts for the Global Urological Disorders Market 13

3.2.1 Sales Value 13

3.2.2 Annual Cost of Therapy 14

3.2.3 Treatment Usage Patterns 15

3.2.4 Generics' Share in the Global Urological Disorders Market 20

3.3 Urological Disorders Market Drivers 22

3.3.1 Steady Increase in the UI and BPH Prevalence Population 22

3.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH 22

3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 22

3.4 Urological Disorders Market Restraints 23

3.4.1 Unwillingness to Seek Medical Help for UI 23

3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues 23

3.4.3 Non Pharmacological Therapy Recommended for UI and BPH 23

4 Global Urological Disorders Market: Therapeutic Landscape 24

4.1 Benign Prostatic Hyperplasia Market 24

4.1.1 Introduction 24

4.1.2 Sales Value 24

4.1.3 Annual Cost of Therapy 26

4.1.4 Treatment Usage Patterns 27

4.1.5 Market Share by Geography 32

4.1.6 Generics' Share of the Global BPH Market 35

4.2 Urinary Incontinence (UI) Market 36

4.2.1 Introduction 36

4.2.2 Sales Value 37

4.2.3 Annual Cost of Therapy 39

4.2.4 Treatment Usage Patterns 40

4.2.5 Market Share by Geography 45

4.2.6 Generics' Share in the Global UI Market 49

4.3 Urinary Tract Infections Market 51

4.3.1 Introduction 51

4.3.2 Sales Value 51

4.3.3 Annual Cost of Therapy 53

4.3.4 Treatment Usage Patterns 54

4.3.5 Market Share by Geography 59

4.3.6 Generics' Share of the Global UTI Market 62

5 Global Urological Disorders Market: Geographical Landscape 64

5.1 Geographical Break-up 64

5.2 The US 67

5.2.1 Sales Value 67

5.2.2 Annual Cost of Therapy 68

5.2.3 Treatment Usage Patterns 69

5.3 Top Five Countries in Europe 75

5.3.1 Sales Value 75

5.3.2 Annual Cost of Therapy 76

5.3.3 Treatment Usage Patterns 77

5.4 Japan 83

5.4.1 Sales Value 83

5.4.2 Annual Cost of Therapy 84

5.4.3 Treatment Usage Patterns 85

6 Global Urological Disorders Market: Pipeline Analysis 90

6.1 Introduction 90

6.1.1 Research and Development Pipeline – UI 91

6.1.2 Research and Development Pipeline – BPH 93

6.1.3 Research and Development Pipeline – UTI 95

6.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 97

6.2.1 Botulinum Toxin A 97

6.2.2 YM178 98

6.2.3 NX-1207 98

6.2.4 PRX302 99

6.2.5 NXL104/ceftazidime 100

7 Global Urological Disorders Market: Competitive Landscape 101

7.1 Market Share Analysis: Urological Disorders 101

7.2 Competitive Profiling 103

7.2.1 Astellas Pharma 103

7.2.2 Johnson and Johnson (J&J) 104

7.2.3 Pfizer 106

7.2.4 GlaxoSmithKilne (GSK) 107

7.2.5 Sanofi-Aventis 108

8 Global Urological Disorders Market: Strategic Consolidations 110

8.1 Overview 110

8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 112

8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 112

8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 112

8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 112

8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 112

8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 112

8.2 R&D Licensing Agreements 113

8.2.1 Deals by Indication 113

8.2.2 Deals by Phase 114

8.2.3 Deals by Geography 114

8.2.4 Deals by Licensing Type 115

8.2.5 Deals by Value ($) 115

8.2.6 Phase I 116

8.2.7 Phase II 117

8.2.8 Approved 118

9 Global Urological Disorders Market: Appendix 120

9.1 Market Definitions 120

9.2 Abbreviations 120

9.3 Research Methodology 121

9.3.1 Coverage 121

9.3.2 Secondary Research 121

9.3.3 Primary Research 122

9.3.4 Forecasts 122

9.3.5 Expert Panel Validation 124

9.4 Contact Us 125

9.5 Disclaimer 125

9.6 Sources 125

1.1 List of Tables

Table 1: Urological Disorders Market, Global, Sales Value ($bn), 2001–2009 13

Table 2: Urological Disorders Market, Global, Sales Value ($bn), 2009–2016 13

Table 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009 14

Table 4: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 15

Table 5: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2001–2009 16

Table 6: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2009–2016 16

Table 7: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2001–2009 21

Table 8: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2009–2016 21

Table 9: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2009 25

Table 10: Urological Disorders Market, Global, BPH Sales Value ($bn), 2009–2016 25

Table 11: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2009 26

Table 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2009–2016 27

Table 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2009 27

Table 14: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2009–2016 28

Table 15: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2009 33

Table 16: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2009–2016 34

Table 17: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2009 35

Table 18: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2009–2016 36

Table 19: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2009 38

Table 20: Urological Disorders Market, Global, UI Sales Value ($bn), 2009–2016 38

Table 21: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2009 39

Table 22: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2009–2016 39

Table 23: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2009 40

Table 24: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2009–2016 41

Table 25: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2009 47

Table 26: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2009–2016 47

Table 27: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2009 49

Table 28: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2009–2016 50

Table 29: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2009 52

Table 30: Urological Disorders Market, Global, UTI Sales Value ($bn), 2009–2016 52

Table 31: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2009 53

Table 32: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2009–2016 53

Table 33: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2009 54

Table 34: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2009–2016 55

Table 35: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2009 60

Table 36: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2009–2016 61

Table 37: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2009 62

Table 38: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2009–2016 62

Table 39: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009 65

Table 40: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016 65

Table 41: Urological Disorders Market, US, Sales Value ($bn), 2001–2009 67

Table 42: Urological Disorders Market, US, Sales Value ($bn), 2009–2016 68

Table 43: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2009 68

Table 44: Urological Disorders Market, US, Annual Cost of Therapy ($), 2009–2016 69

Table 45: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2009 70

Table 46: Urological Disorders Market, US, Treatment Usage Patterns (million), 2009–2016 70

Table 47: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009 75

Table 48: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 76

Table 49: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 77

Table 50: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 77

Table 51: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009 78

Table 52: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 78

Table 53: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2009 83

Table 54: Urological Disorders Market, Japan, Sales Value ($bn), 2009–2016 84

Table 55: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009 84

Table 56: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 84

Table 57: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009 85

Table 58: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 86

Table 59: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market, AUG 2010 92

Table 60: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market, AUG 2010 94

Table 61: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market, AUG 2010 96

Table 62: Urological Disorders Market, Global, Major M&A Deals, 2004-2009 111

Table 63: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2004 116

Table 64: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase II Stage, 2004–2010 117

Table 65: Urological Disorders Market, Global, Licensing Agreements for Approved Drugs, 2008–2010 118

1.2 List of Figures

Figure 1: Urological Disorders Market, Global, Drivers and Restraints, 2009 11

Figure 2: Urological Disorders Market, Global, Sales Value ($bn), 2001–2016 12

Figure 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016 13

Figure 4: Urological Disorders Market, Global, Therapeutic Usage Patterns (million), 2001–2016 14

Figure 5: Urological Disorders Market, Global, Diseased Population (million), 2001–2016 16

Figure 6: Urological Disorders Market, Global, Treatment Seeking Population (million), 2001–2016 17

Figure 7: Urological Disorders Market, Global, Diagnosis Population (million), 2001–2016 18

Figure 8: Urological Disorders Market, Global, Prescription Population (million), 2001–2016 19

Figure 9: Urological Disorders Market, Global, Branded Vs Generics ($bn), 2001–2016 20

Figure 10: Urological Disorders Market, Global, Market Indicators, 2009 21

Figure 11: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2016 24

Figure 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2016 25

Figure 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2016 26

Figure 14: Urological Disorders Market, Global, BPH Diseased Population (million), 2001–2016 27

Figure 15: Urological Disorders Market, Global, BPH Treatment Seeking Population (million), 2001–2016 28

Figure 16: Urological Disorders Market, Global, BPH Diagnosis Population (million), 2001–2016 29

Figure 17: Urological Disorders Market, Global, BPH Prescription Population (million), 2001–2016 30

Figure 18: Urological Disorders Market, Global, BPH Market Segmentation by Geography (%), 2009 and 2016 31

Figure 19: Urological Disorders Market, Global, BPH Market in the Top Five Countries in Europe (%), 2009 and 2016 31

Figure 20: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2016 32

Figure 21: Urological Disorders Market, Global, BPH Market, Geography Benchmarking, 2009 33

Figure 22: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2016 34

Figure 23: Urological Disorders Market, Global, BPH Market, Generics Share (%), 2009 and 2016 35

Figure 24: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2016 37

Figure 25: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2016 38

Figure 26: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2016 39

Figure 27:Urological Disorders Market, Global, UI Diseased Population (million), 2001–2016 40

Figure 28:Urological Disorders Market, Global, UI Treatment Seeking Population (million), 2001–2016 41

Figure 29:Urological Disorders Market, Global, UI Diagnosis Population (million), 2001–2016 42

Figure 30: Urological Disorders Market, Global, UI Prescription Population (million), 2001–2016 43

Figure 31: Urological Disorders Market, Global, UI Market Segmentation by Geography (%), 2009 and 2016 44

Figure 32: Urological Disorders Market, Global, UI Market in the Top Five Countries in Europe (%), 2009 and 2016 44

Figure 33: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2016 45

Figure 34: Urological Disorders Market, Global, UI Market, Geography Benchmarking, 2009 47

Figure 35: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2016 48

Figure 36: Urological Disorders Market, Global, UI Market, Generics Share (%), 2009 and 2016 49

Figure 37: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2016 51

Figure 38: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2016 52

Figure 39: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2016 53

Figure 40: Urological Disorders Market, Global, UTI Diseased Population (million), 2001–2016 54

Figure 41: Urological Disorders Market, Global, UTI Treatment Seeking Population (million), 2001–2016 55

Figure 42: Urological Disorders Market, Global, UTI Diagnosis Population (million), 2001–2016 56

Figure 43: Urological Disorders Market, Global, UTI Prescription Population (millions), 2001–2016 57

Figure 44: Urological Disorders Market, Global, UTI Market Segmentation by Geography (%), 2009 and 2016 58

Figure 45: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2016 59

Figure 46: Urological Disorders Market, Global, UTI Market, Geography Benchmarking, 2009 60

Figure 47: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2016 61

Figure 48: Urological Disorders Market, Global, UTI Market, Generics Share (%), 2009 and 2016 62

Figure 49: Urological Disorders Market, Global, Market Share by Geography (%), 2009 and 2016 63

Figure 50: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016 64

Figure 51: Urological Disorders Market, Global, Geography Benchmarking, 2009 and 2016 65

Figure 52: Urological Disorders Market, US, Sales Value ($bn), 2001–2016 66

Figure 53: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2016 67

Figure 54: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2016 69

Figure 55: Urological Disorders Market, US, Diseased Population (million), 2001–2016 70

Figure 56: Urological Disorders Market, US, Treatment Seeking Population (million), 2001–2016 71

Figure 57: Urological Disorders Market, US, Diagnosis Population (million), 2001–2016 72

Figure 58: Urological Disorders Market, US, Prescription Population (million), 2001–2016 73

Figure 59: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016 74

Figure 60: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 75

Figure 61: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016 76

Figure 62: Urological Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016 78

Figure 63: Urological Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016 79

Figure 64: Urological Disorders Market, Top Five Countries in Europe, Diagnosis Population (million), 2001–2016 80

Figure 65: Urological Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016 81

Figure 66: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2016 82

Figure 67: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016 83

Figure 68: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016 84

Figure 69: Urological Disorders Market, Japan, Diseased Population (million), 2001–2016 85

Figure 70: Urological Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016 86

Figure 71: Urological Disorders Market, Japan, Diagnosed Population (million), 2001–2016 87

Figure 72: Urological Disorders Market, Japan, Prescription Population (million), 2001–2016 88

Figure 73: Urological Disorders Market, Global, R&D Pipeline by Indication (%), AUG 2010 89

Figure 74: Urological Disorders Market, Global, R&D Pipeline by Phase (%), AUG 2010 90

Figure 75: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market (%), AUG 2010 92

Figure 76: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market (%), AUG 2010 94

Figure 77: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market (%), AUG 2010 95

Figure 78: Urological Disorders Market, Global, Market Share of Top Manufacturers (%), 2009 100

Figure 79: Urological Disorders Market, Global, Revenue of Top Five Players ($m), 2007–2009 101

Figure 80: Urological Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2007–2009 102

Figure 81: Urological Disorders Market, Global, SWOT- Astellas Pharma, 2010 103

Figure 82: Urological Disorders Market, Global, SWOT- Johnson & Johnson, 2010 105

Figure 83: Urological Disorders Market, Global, SWOT- Pfizer, 2010 106

Figure 84: Urological Disorders Market, Global, SWOT- GlaxoSmithKline, 2010 107

Figure 85: Urological Disorders Market, Global, SWOT- Sanofi-Aventis, 2010 108

Figure 86: Urological Disorders Market, Global, M&A Deals by Indication (%), 2009 109

Figure 87: Urological Disorders Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 112

Figure 88: Urological Disorders Market, Global, Major Licensing Agreements By Phase (%), 2005–2010 113

Figure 89: Urological Disorders Market, Global, Major Licensing Agreements By Geography (%), 2004–2010 113

Figure 90: Urological Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2004–2010 114

Figure 91: Urological Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004–2010 114

Figure 92: GBI Research Market Forecasting Model 123

Companies mentioned

Astellas Pharma

Johnson and Johnson (J&J)

Pfizer

GlaxoSmithKilne (GSK)

Sanofi-Aventis

To order this report:

Pathology Industry: Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators
2. Reportlinker Adds Hip and Knee Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
3. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
4. Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China
5. Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge
6. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
7. Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017
9. Reportlinker Adds Insulin Pumps - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
10. Reportlinker Adds Threats to Avastin - Targeting the VEGF Pathway
11. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty healthcare ... conditions, announced today that the Company will present its ... on Tuesday, February 16, 2016, at 4:30 p.m. ET.  ... overview of its business and growth strategy, as well ... 31, 2015. --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development of a once-daily, oral therapy for ... Chief Medical Officer, Dr. Maya Halpern , has notified ... Chief Medical Officer and from its Board of Directors ... reaching retirement age. Allen Baharaff . Mr. ...
(Date:2/11/2016)... , February 11, 2016 ... Autoclave Market Report 2016 research report provides information ... regions, development status with crucial statistical data and ... http://www.deepresearchreports.com/142870.html . --> Complete report ... 19 companies and supported with 296 tables and ...
Breaking Medicine Technology:
(Date:2/11/2016)... City, Utah (PRWEB) , ... February 11, 2016 ... ... wireless microFET medical dynamometers and ergoFET force gauges used in physical therapy, occupational ... Rehab Strength Indicator sensor for resistance cord exercise and therapy, introduces its new ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on ... before signing a contract and how to spot an incompetent or dishonest IT person ... e-mail and technology, it’s more important than ever to make sure the company you ...
(Date:2/10/2016)... WASHINGTON (PRWEB) , ... February 10, 2016 , ... ... to expand the ability of Medicare Advantage organizations to deliver medical services via ... , “ATA has been advocating for such language for many years. ...
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
Breaking Medicine News(10 mins):